Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

247.51
-10.4900-4.07%
Pre-market: 248.500.9918+0.40%04:01 EDT
Volume:1.63M
Turnover:404.75M
Market Cap:33.02B
PE:44.05
High:256.68
Open:256.68
Low:246.42
Close:258.00
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:0.82
T/O Rate:1.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:24.39
PE(LYR):106.23

Loading ...

Alnylam initiated with a Buy at Citi

TIPRANKS
·
May 19

Alnylam’s New Phase 1 ALN-4915 Trial: Early Safety Data in Focus for ALNY Investors

TIPRANKS
·
May 15

PLTR, KTOS, ALNY: 3 High P/E Stocks with 40%+ Upside Potential in 2026

TIPRANKS
·
May 13

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-05-12

Reuters
·
May 13

Alnylam announces new analyses from HELIOS-B study of vutrisiran

TIPRANKS
·
May 12

Alnylam says HELIOS-B analysis shows vutrisiran benefit across ATTR-CM patient groups

Reuters
·
May 12

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across Attr-Cm Patient Populations, Including Patients With a High Disease Burden

THOMSON REUTERS
·
May 12

Alnylam to webcast investor conference presentations at BofA, Goldman Sachs healthcare events

Reuters
·
May 07

Tenaya Therapeutics Q1 net loss widens, misses analyst expectations

Reuters
·
May 07

Vir Biotechnology Q1 net loss widens

Reuters
·
May 07

Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Alnylam presents new vutrisiran analyses at Heart Failure congress

Reuters
·
May 04

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in Attr-Cm

THOMSON REUTERS
·
May 04

Alnylam price target raised to $370 from $360 at Morgan Stanley

TIPRANKS
·
May 01

Alnylam price target lowered to $447 from $448 at Bernstein

TIPRANKS
·
May 01

Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
May 01

RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating

MT Newswires Live
·
May 01

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Alnylam Pharma (ALNY) and Avantor (AVTR)

TIPRANKS
·
May 01

Alnylam Pharma (ALNY) Gets a Buy from Bernstein

TIPRANKS
·
May 01

Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 01